Corrigendum to 'Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study' [Eur J Canc 81 (2017) 17-25].
作者信息
Chau Ian, Peck-Radosavljevic Markus, Borg Christophe, Malfertheiner Peter, Seitz Jean Francois, Park Joon Oh, Ryoo Baek-Yeol, Yen Chia-Jui, Kudo Masatoshi, Poon Ronnie, Pastorelli Davide, Blanc Jean-Frederic, Chung Hyun Cheol, Baron Ari D, Okusaka Takuji, Bowman L, Cui Zhanglin Lin, Girvan Allicia C, Abada Paolo B, Yang Ling, Zhu Andrew X
机构信息
Royal Marsden Hospital, London and Surrey, United Kingdom.
Allgemeines Krankenhaus Wien, Vienna and Klinkum Klagenfurt am Wörthersee, Klagenfurt, Austria.
出版信息
Eur J Cancer. 2018 Sep;100:135-136. doi: 10.1016/j.ejca.2018.06.002. Epub 2018 Jun 30.
PMID:29970352
Abstract
摘要
Zotero 插件